Abstract
After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Current Pharmaceutical Design
Title: Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders
Volume: 17 Issue: 15
Author(s): Meredith Broderick and Tony Masri
Affiliation:
Keywords: Histamine, H3 receptor, H3R antagonists, histamine H3 receptor H3R inverse agonists, narcolepsy treatment, excessive daytime sleepiness, antihistamine, sleepiness, narcolepsy, metabotropic, tuberomammillary, diurnal, orexin, preoptic, accumbens, globus pallidus, substantia nigra, presynaptically, norepinephrine, thioperamide
Abstract: After the discovery and characterization of the H3R and H4R receptors, they have become widely anticipated as potential therapeutic agents in the treatment of sleep disorders. In preliminary studies, histamine H3 receptor (H3R) antagonists and inverse agonists have demonstrated promise in the treatment of sleep disorders associated with excessive daytime sleepiness. This review article summarizes the current research in this area and characteristics of H3R and H3R antagonists and inverse agonists in development.
Export Options
About this article
Cite this article as:
Broderick Meredith and Masri Tony, Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197133
DOI https://dx.doi.org/10.2174/138161211796197133 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Acetylcholinesterase and Prolyl Oligopeptidase Inhibition of Novel Amino acid-functionalized Stigmasterol and Ursolic Acid Derivatives
Current Organic Chemistry Advances in Drug Discovery to Assess Cholinergic Neurotransmission: A Systematic Review
Current Drug Discovery Technologies Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Current Alzheimer Research Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Nitric Oxide’s Involvement in the Spectrum of Psychotic Disorders
Current Medicinal Chemistry Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Drug Safety Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study
Current Alzheimer Research GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data
Current Alzheimer Research An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets A Novel Relationship for Schizophrenia, Bipolar and Major Depressive Disorder Part 6: A Hint from Chromosome 6 High Density Association Screen
Current Molecular Medicine Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry Neuroprotective Therapies for Alzheimers Disease
Current Pharmaceutical Design Susceptibility Genes in Hypertension
Current Pharmaceutical Design Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Alzheimerss Disease, Dementia and Cognitive Decline (Executive Editors: J.E. Starrett, Jr. and G.S. Poindexter)]
Current Pharmaceutical Design